Drug intelligence / Profile preview

cyclophosphamide + doxorubicin + paclitaxel + pazopanib

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

This is a combination of four anticancer drugs. The first three (cyclophosphamide + doxorubicin + paclitaxel) are commonly used together in breast cancer treatment, typically with doxorubicin and cyclophosphamide (AC) administered first, followed by paclitaxel. Pazopanib is a tyrosine kinase inhibitor primarily used for renal cell carcinoma and soft tissue sarcomas. This specific four-drug combination does not appear to be a standard regimen in clinical practice based on the available information.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))DNATOP2A (DNA topoisomerase II)PDGFR (PDGFR family)

Beyond the preview

Go deeper on cyclophosphamide + doxorubicin + paclitaxel + pazopanib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + doxorubicin + paclitaxel + pazopanib.

Explore the full profile